Concepedia

Yihebali Chi

YC

Statistics

Publications

34

Citations

3.2K

H-Index

20

Active since

2011

Affiliations

Chinese Academy of Medical Sciences & Peking Union Medical College(Current)

Sun Yat-sen University

Sun Yat-sen University Cancer Center

Fudan University Shanghai Cancer Center

Peking University

Yihebali Chi is an author at Chinese Academy of Medical Sciences & Peking Union Medical College specializing in medicine, oncology, and pharmacology.

ORCID

Publications per year

2011–2023

34

Publications

34

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

Jin Li, Shukui Qin, Rui‐Hua Xu et al. · The Lancet Oncology · 2015 · 816 citations

, , +10

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

Yongkun Sun, Wei Niu, Feng Du et al. · Journal of Hematology & Oncology · 2016 · 431 citations · Full text

, , +15

Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma

Yihebali Chi, Zhiwei Fang, Xiaonan Hong et al. · Clinical Cancer Research · 2018 · 332 citations

, , +17

Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study

Jianming Xu, Lin Shen, Zhiwei Zhou et al. · The Lancet Oncology · 2020 · 190 citations

, , +8

Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study

Jianming Xu, Lin Shen, Chunmei Bai et al. · The Lancet Oncology · 2020 · 189 citations

, , +11

1–5 of 34